COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
Ivermectin study #37 of 63
12/1 Early treatment study
Alonso et al., (Preprint)
COVID-19: Uso de ivermectina
Source   PDF   Share   Tweet
Observational study in Argentina showing significantly lower mortality in the 60 days after adopting ivermectin compared to the 60 days before, relative risk RR 0.082, p=0.003.

Alonso et al., 12/1/2020, retrospective, Argentina, South America, preprint, 1 author, dosage not specified.
risk of death, 91.8% lower, RR 0.08, p = 0.009, treatment 1 of 311 (0.3%), control 5 of 128 (3.9%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 63 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit